The EU Pharmaceutical Package is more than a regional reform – it is part of a broader global shift in how innovation, access and competition are being recalibrated. This panel moves beyond an EU-centric lens to examine how different policy models are evolving in parallel: Europe’s rebalancing towards access and sustainability, the continued reliance of the US on strong IP protection and market-driven incentives, and China’s acceleration through investment and speed.
Against this backdrop, the discussion will focus on a central question: where will innovation go next? Panelists will explore how global pharmaceutical companies may need to adapt their IP, litigation and investment strategies in response to diverging regulatory and competitive dynamics across key jurisdictions.